

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

1<sup>st</sup> August 2025

Company:	Chordia Therapeutics, Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Representative Ami Kira

**Notice of Commencement of Joint Research  
with Senju Pharmaceutical Co., Ltd.**

Kanagawa Japan

1<sup>st</sup> August 2025 –Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) and Senju Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Osaka City; President & CEO: Shuhei Yoshida, “Senju Pharmaceutical”) today announce the execution of a joint research agreement (“Joint Research”) to develop a drug for ophthalmic diseases using the compound with GCN2 kinase inhibitory activity (“the Compound”) from Chordia’s anti-cancer drug pipeline.

In the Joint Research, Senju Pharmaceutical and Chordia will leverage technologies, resources, and expertise of both parties in pharmaceutical R&D to pursue the creation of novel therapy for ophthalmic diseases. Chordia will provide know-how and research materials related to the Compound, while Senju Pharmaceutical will utilize its extensive experience and knowledge in the ophthalmology field to evaluate the Compound’s potential as a therapeutic agent through pharmacology studies. Upon completion of the Joint Research, in case the parties are willing to pursue business opportunities based on the research outcomes, discussions will be held regarding the grant of exclusive negotiation rights and other related terms.

The scope of the Joint Research is limited to the investigation of the Compound’s potential in treating ophthalmic diseases. Chordia will continue to explore R&D and business partnership opportunities for other indications within its anti-cancer drug pipeline.

And this Joint Research is not in direct competition with the collaboration announced on July 8, 2025, with D. Western Therapeutics Institute, Inc. Chordia intends to explore new possibilities in the ophthalmic field for two distinct compounds in collaboration with partners.

The impact of this matter on our business results is expected to be minor.

---

**About Senju Pharmaceutical Co., Ltd.**

Since its founding in 1947, Senju Pharmaceutical Co., Ltd. (“Senju”) has dedicated over 70 years to providing innovative, high-quality pharmaceuticals and services, primarily in the field of ophthalmology. Through unique ideas and strong research and development, Senju has consistently contributed to advancing eye care. Under the slogan, “Beyond eyesight,” Senju continues to focus on the global medical field—especially ophthalmology—pursuing development of new drugs with flexible thinking and a spirit of exploration. Senju aims to remain a trusted and indispensable company by continuously creating and providing innovative pharmaceuticals and services that enhance and preserve “a joy to behold” or QOV (Quality of Vision) for patients worldwide. For more information, please visit the Senju website: <https://www.senju.co.jp/>

**About Chordia Therapeutics**

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.